3 results about "ERBB4" patented technology

The application belongs to the technical field of biological medicine, and discloses application of ERBB4 as a treatment target in neuroblastoma treatment. The application discloses application of a reagent for detecting ERBB4 in preparation of a product for evaluating treatment efficacy of neuroblastoma. The application proves that ERBB4 is a potential risk factor for high-risk neuroblastoma recurrence through multi-omics research and mechanism analysis of metabolic regulation network of ERBB4, and verifies the preclinical application value of the target point through a verification test, thereby providing a new target point with stable expression for precise diagnosis and treatment of refractory and recurrent neuroblastoma. Experiments prove that high expression of ERBB4 plays an inhibitory role on neuroblastoma by activating immune effect, improves the response rate of neuroblastoma to chemotherapy and immunotherapy, improves the overall treatment efficiency, has good clinical transformation value, and has important significance for the treatment of neuroblastoma.

The invention relates to the field of neurological rehabilitation medicine, and particularly discloses application of task-oriented training in promoting functional recovery after spinal cord injury (SCI). The invention is based on the discovery that task-oriented training (such as single globule grasping training) can activate an NRG1 / ErbB4 signaling pathway by up-regulating the phosphorylation level of neuro-regulatory protein-1 (NRG1) and a receptor ErbB4 of the NRG1, thereby promoting regenerative cortical spinal bundle (CST) axons and spinal motor neurons to form functional excitatory synapses and inducing the conversion of synaptic phenotypes to excitatory. The invention provides a treatment method including task-oriented training and a combined strategy for combined application of the treatment method and a treatment method for activating endogenous axon regeneration capacity (such as by inhibiting PTEN expression), the treatment method is used for improving upper limb movement dysfunction after spinal cord injury, particularly after neck injury, and a new scheme is provided for clinical treatment.

The invention belongs to the technical field of biological medicines, and discloses an scFV fragment and application thereof in preparation of a medicine for treating neuroblastoma. The invention discloses an scFV (single chain factor virus) antibody for resisting ERBB4 (endothelial cell binding protein 4). By designing an scFV fragment specifically combined with an ERBB4 extracellular domain and meanwhile designing ERBB4. CAR T, experimental verification shows that compared with traditional CD3 + T cells, CART designed by targeting ERBB4 extracellular domain scFV can effectively activate T cells after co-culture with NB cells and has a stronger tumor killing effect, the feasibility of the ERBB4. CAR T for preventing NB development and recurrence is prompted, and the CART has a good application prospect. The fusion protein has a good clinical transformation value, and has an important significance in treatment of neuroblastoma.